Xilio Therapeutics (XLO) : 3-year performance

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 73
• Founded in 2016 
• Headquartered in Waltham, Massachusetts
• https://xiliotx.com

Ticker: XLO

October 22, 2021 : initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share.